Implantation of olfactory ensheathing glia (OEG) is a promis-
Introduction
Injured axons in the mammalian spinal cord fail to regenerate across the lesion site and do not re-establish synaptic contacts with their targets. As a consequence, severe damage to the spinal cord usually results in long-lasting deficits, involving partial or complete paralysis and loss of sensation below the level of the injury. The development of new strategies to treat such injuries is a major clinical challenge to neuroscience.
The paucity of axon regeneration in the mature central nervous system (CNS) is thought to depend on a critical molecular balance between growth-promoting and -inhibiting cues. 1 Transient and insufficient upregulation of intrinsic growth-associated proteins, eg B-50/GAP-43, 2 decreased neurotrophic factor signalling, 3 and the presence of many inhibitors for axon growth at the lesion site, [4] [5] [6] [7] [8] [9] are thought to be responsible for this regenerative failure. As a strategy to overcome the inhibitory nature of the scar, implantation of biological substrates in the lesion site that favour axonal growth has been investigated extensively. Because the peripheral nervous system (PNS) regenerates quite successfully, peripheral nerves and associated cells have been employed as cellular conduits to stimulate CNS regeneration. [10] [11] [12] [13] Although some success has been achieved, axonal regeneration was still limited and most regrowing axons were not able to leave the graft and re-enter the CNS tissue distal from the injury. This is likely to be due to many factors, including the inhibitory environment of the CNS, scarring at the distal graft-host interface, 14 and the growth-promoting influence of the graft itself. 15 Over the past few years there has been increasing interest in using another glial cell type, the olfactory ensheathing glia (OEG) cell. 16 Under normal circumstances OEG guide new primary olfactory axons growing from the olfactory epithelium towards their targets, the olfactory bulb glomeruli, where they synapse on, for instance, the dendrites of mitral cells. Since the olfactory bulb is part of the CNS, which is usually regarded as non-permissive tissue for axon growth, OEG are thought to provide a unique cellular boundary between the PNS and CNS. The presence of OEG is thought to allow growing axons of newly generated primary olfactory neurons to cross the transition zone between PNS and CNS and extend processes in the olfactory bulb without inhibition.
The properties of OEG that support axon growth from PNS into CNS tissue are not restricted to the olfactory bulb. This was demonstrated in an experiment where OEG were implanted in the dorsal root entry zone allowing lesioned dorsal root axons to regenerate across the non-permissive barrier of astrocytes at the PNS-CNS transition zone and to enter the spinal cord. 17 These results indicate that, in contrast to the Schwann cells present in the dorsal root, implanted OEG were able to intermingle with scar tissue creating permissive zones for growing axons. Recent studies have reported encouraging results of regeneration in the injured spinal cord following OEG implantation, 18 accompanied by functional improvement in locomotion behaviour. 19, 20 A study using Schwann cell bridges 'capped' with OEG implants in a complete transected spinal cord, showed that the presence of OEG at the lesion site enhanced long-distance axonal regeneration, indicating possible advantages of OEG implants over Schwann cell grafts. 21, 22 This was supported by recent evidence showing that OEG can intermingle with co-cultured astrocytes unlike Schwann cells which form islands in the presence of astrocytes with very little interaction. 23 Furthermore, OEG do not induce expression of inhibitory proteoglycans at the glial surface. 23 Although these results demonstrated that OEG implants support regeneration and may have several advantages over the use of Schwann cells in CNS injury paradigms, the number of regenerating axons distal from the injury site was still limited.
In the present study, the possibilities of ex vivo viral vector-mediated gene transfer to OEG using adeno-, adeno-associated and lentiviral vector systems were examined. Adenoviral (AdV), adeno-associated viral (AAV) and lentiviral (LV) vector systems are widely used as novel tools for the introduction of foreign genes in neural tissue, either by direct injection of the vector into the nervous system or indirect ex vivo gene transfer techniques. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Transferring genes of interest into OEG would not only allow better monitoring of the behaviour of implanted cells in the injured spinal cord and to study the relationship between OEG and regenerating axons, but would also permit the insertion of additional neurotrophic genes into the cells. This could significantly improve the growth-promoting properties of OEG since limited neurotrophic factor expression and differences in the capacity of various axonal populations to regenerate through OEG implants have been reported. [35] [36] [37] [38] Previous studies have reported that delivery of neurotrophic factors using different genetically engineered cellular conduits, such as Schwann cells or fibroblasts, can encourage axon regeneration in the injured spinal cord. [39] [40] [41] [42] All studies described increased sprouting of various axonal populations but, in most cases, the majority of regenerating axons was rerouted around the transplant and few fibres were seen distal to the site of injury. OEG implants may be better candidates for neurotrophic factor delivery since they can reduce the problem of regenerating axons to re-enter the distal part of the spinal cord and have advantages over the use of genetically engineered fibroblasts which are non-CNS in origin and may become tumorigenic.
Results

Ex vivo transduction of purified OEG
Three different viral vector systems (AAV, AdV and LV vectors; Figure 1 ) were tested for their capability to transfer foreign genes into purified cultures of adult rat OEG (Figure 2 ). Under the specific culture conditions used, virtually no transduction of primary OEG cultures was seen following infection with AAV type 2 (AAV-2) vectors encoding green fluorescent protein (GFP) up to 7 days after infection, even with extremely high multiplicity of infection (MOI) up to 1000. The quality and transducing capability of used AAV-GFP stocks was confirmed on human embryonic kidney (HEK) 293T cells that were infected in parallel with OEG cultures and showed efficient transduction, even at lower MOI (MOI 25), within 24 h following AAV-2 infection (see insert Figure  2 ). In contrast to AAV-2, AdV and LV vectors encoding either the bacterial marker enzyme ␤-galactosidase (␤-gal; AdV-LacZ) or GFP (LV-GFP), respectively, efficiently transferred the gene of choice into cultured OEG. Many transduced cells expressing high levels of transgenic protein were observed at 3 days after infection. The efficiency of transduction increased in parallel with higher MOI (data not shown), with optimal MOI of 100 and 50 for AdV and LV, respectively. The optimal MOI was defined as the lowest dose of viral vector that was needed to transduce all cultured cells. To ascertain that the insertion of a new gene using viral vector-mediated gene transfer did not interfere with normal cell functioning, AdV vector-and LV vector-infected OEG cultures were phenotypically examined for expression of the general cell markers low-affinity neurotrophin receptor p75 NTR , Schwann cell marker S-100, and glial-fibrillary acidic protein (GFAP). No changes in cellular phenotype and cell marker expression were found ( Figure 3 ).
AdV vector-mediated transgene expression in OEG implants
Suspensions of AdV-LacZ transduced OEG (MOI 100) were gently injected (1 l; 100 000 cells) into the spinal cord immediately after unilateral lesion of the cervical (C4) rubrospinal tract (RST), both rostrally and caudally, at 1 mm distance from the lesion site ( Figure 4) . Analysis of transgene expression 7 days after implantation showed many ␤-gal-positive cells in the lesion area. All transgene-expressing cells were present in the Hoechst-positive area as expected since OEG were pre-labelled with Hoechst dye before implantation. Adjacent sections stained for p75 NTR showed that ␤-gal-positive cells could be identified as p75 NTR -positive OEG, and were present in the centre of the lesion as determined by GFAP staining. Although a very low level of diffuse GFAP staining was found in p75 NTR -purified OEG in vitro, the levels of GFAP immunostaining in reactive astrocytes were too high to allow visualisation of co-localisation between GFAP and p75 NTR signal in OEG implants (Figure 7a ). Analysis at later survival points, 14 and 30 days after implantation respectively, showed a significant decline in the number of ␤-gal-expressing cells. Nevertheless, the detection of Hoechst-labelled cells implied that implanted OEG were still present at the lesion site. In contrast to the number of transgene-expressing cells, an increased number of p75 NTR -positive cells was observed compared with 7 days after implantation. Interestingly, at all time-points analysed, a discrepancy was observed in the overlap between Hoechst dye and p75 NTR immunoreactivity. Many Hoechst-labelled nuclei were observed outside the p75 NTR -positive area suggesting leakage of Hoechst label from implanted cells into the surrounding tissue (Figure 4 and 7a) . Visualisation of the lesion area using GFAP staining revealed that, based on p75 immunoreactivity, implanted OEG remained present at the lesion site, but OEG did not migrate over large distances both rostrally and caudally into the spinal cord as suggested by the distribution of Hoechst labelling. Although intermingling of implanted OEG and reactive astrocytes at the borders of the lesion was observed, no sign of OEG migration at further distances, both proximal and distal from the lesion, was found.
Implantation of AdV-LacZ-transduced OEG in the intact spinal cord resulted in persistent expression of the transgene for at least 30 days ( Figure 5 ). No decrease in expression was observed over time and many ␤-gal-positive cells were detected up to 30 days after implantation. Transgene-expressing cells were identified as implanted OEG based on Hoechst labelling and p75 NTR staining. Staining for GFAP showed mild gliosis at the injection site, but no major tissue damage due to the injection procedure. Again, many Hoechst-positive nuclei displaying no immunoreactivity for both ␤-gal and p75 NTR were detected in the neighbouring tissue surrounding the implant suggesting leakage of Hoechst label.
LV vector-mediated transgene expression in OEG implants
Suspensions of LV-GFP transduced OEG (MOI 50) were injected into the unilaterally lesioned C4 spinal cord as described above. Ex vivo transduction of OEG using LV vectors resulted in a persistent GFP expression, at least up to 4 months after implantation ( Figure 6 ). Many GFPpositive cells were detected at survival points of 7, 14, 30 days and 4 months, respectively. Double staining for p75 NTR was used to examine whether GFP-positive cells could be identified as implanted OEG. Most GFP-labelled cells were immunoreactive for p75 NTR , which, together with the characteristic bipolar morphology, showed them to be implanted OEG (Figure 7b ). Again, intermingling of OEG and reactive astrocytes did occur, and no migration of OEG, either rostrally or caudally, across the astrocytic barrier into the spinal cord was observed ( Figures 6 and 7c ). All GFP-labelled cells were detected close to the original injection site, encapsulated by an astrocytic scar. Once more, due to differences in the expression levels of GFAP between OEG and reactive astrocytes, no co-localisation of GFAP and p75 NTR signal
Gene Therapy could be visualised in OEG in vivo ( Figure 7b ). Additional triple stainings were used to visualise GFP-positive implanted OEG, the astrocytic scar, and neurofilament (NF)-positive axonal profiles at the lesion site. At 4 months after lesion, numerous NF-positive axon-like structures were detected in the implant itself, often in close contact with GFP-labelled OEG ( Figure 7c ).
Discussion
Implantation of OEG in the injured spinal cord has been reported to promote long-distance regeneration and functional recovery following spinal cord injury. 43 In the present study, we have investigated the possibility of ex vivo gene transfer to OEG. Three different vector systems were tested and found to behave differently in their capability to transduce OEG. Under the tissue culture conditions used, virtually no transduction of OEG was found following infection with AAV-2 vectors. This observation is in agreement with a previous study showing that Schwann cells, a cell type that is phenotypically related and very similar to OEG, are normally resistant to AAV-2 infection. 44 Moreover, preferential transduction of nonglial cells by AAV-2 vectors has been reported in the CNS. 29 The failure of AAV-2 vectors to transduce primary OEG might be due to the fact that these cells lack membrane-associated heparan sulphate proteoglycan, a component of the receptor for AAV particles. 45 In contrast to AAV-2, efficient transduction of OEG was observed by AdV and LV vectors. No changes in morphology and expression of general cell marker proteins (see Ref. 16) were detected after transduction with these vectors. Following ex vivo gene transfer with both AdV or LV vectors, implants of transduced OEG into the site of a spinal cord lesion were p75 NTR -positive, displayed typical bipolar OEG morphology, and high levels of transgenic protein could be detected during the first week after implantation. These findings suggest that gene transfer with AdV and LV vectors did not interfere with normal cell functioning.
Transgene expression in OEG implants subjected to AdV, but not LV vector-mediated gene transfer gradually decreased during the first month after implantation. Direct toxicity of AdV vectors, immunological rejection of implanted OEG, downregulation of cytomegalovirus (CMV) promoter activity, and the loss of recombinant viral genome may have contributed to this loss of transgene expression. Proliferation of implanted OEG at the lesion site may be the most likely cause for the observed decline in transgene expression because no loss of expression was observed in the intact spinal cord. Since first-generation E1-deleted AdV vectors do not integrate into the host genome or autoreplicate, the episomally located vector genome will be lost during the process of mitosis resulting in a concomitant decline in transgene expression. 46 Recently, members of the neuregulin family were described as survival factors for OEG and able to induce a mitogenic response in these cells. 47, 48 Interestingly, these neuregulins are highly expressed by reactive astrocytes at the lesion site in the injured CNS. 49 In the intact spinal cord, only minimal proliferation of OEG is expected because of very little astrocytic scarring and contact inhibition. Based on the increase in p75 NTR immunoreactivity over time, proliferation of implanted OEG in the lesioned spinal cord seems to occur although the additional staining for p75 NTR could also be due to Schwann cells that have been reported previously to invade spinal cord lesion sites. 50 Since there are no cellular markers to distinguish between host Schwann cells and implanted OEG, this possibility cannot be ruled out completely. However, the use of stable LV vector transduced OEG implants, expressing GFP as a specific and reliable marker to visualise implanted OEG, clearly showed that the vast majority of GFP-labelled cells coexpressed p75 NTR . Immunoreactivity for p75
Figure 2 Transduction of primary OEG cultures. (Top) Immunocytochemistry for GFP at 7 days after infection with AAV-2 vector (MOI 1000). Virtually no transduction of OEG cultures can be observed. In contrast to OEG, infection of HEK 293T cells with the same AAV-GFP (MOI 25; see insert) resulted in efficient transduction
NTR outside the confines of the GFP labelling could only be observed to a minor extent at the lateral edges of the spinal cord, close to the dorsal root entry zone or in the root itself. This demonstrates that there was only very limited invasion of Schwann cells into the injury site which on its own cannot explain the observed increase in p75 NTR labelling. Direct cellular toxicity of AdV vectors has been reported after application directly into the CNS, 51 but not using an ex vivo approach. 52 It is also unlikely that immunological rejection or an inflammatory response against transduced OEG implants was responsible for the decline in transgene expression because syngenic cells were used for implantation and, as described earlier, no loss of transgene expression was found when AdV-transduced OEG were injected into intact spinal cord. Downregulation of CMV promoter activity in certain areas in the CNS has been suggested previously, 29 and may have contributed to the gradual decline in transgene expression. However, persistent AdV-derived ␤-gal expression in OEG implanted into intact spinal cord seems to rule out this possibility as does the fact that no loss of CMV promoter-driven GFP expression was found when using LV vectors.
The transient gene expression in OEG implants, using AdV vector-mediated gene transfer, allows the possibility of manipulating the growth-promoting properties of OEG and microenvironment of the lesion during the acute phase following injury. Interestingly, long-term effects on outgrowth of lesioned corticospinal tract axons have been reported following transient expression of neurotrophins. 53 These long-term effects of transient AdV vector-mediated neurotrophic factor expression are most likely the result of priming of axonal outgrowth, that is thought to counteract the inhibitory activity in the lesion environment. 54 In situations that would require OEG implants displaying prolonged foreign gene expression, eg to promote long-distance regeneration through large contusion lesions, stable transduced OEG may be needed. In agree- ment with our hypothesis that AdV vector-mediated transgene expression was lost as a consequence of degradation and loss of vector DNA during OEG proliferation, ex vivo transduction of OEG using integrating LV vectors resulted in persistent transgene expression for at least 4 months after implantation. Numerous NF-positive axons were detected within the implants and in close association with GFP-labelled OEG. This allows us to start investigating the interactions between implanted OEG and lesioned CNS axons in greater detail. Implantation of stable transduced OEG, using regulatory gene expression if desired, 55 may be a very promising strategy to counteract ongoing degeneration of neural tissue and to stimulate enhanced regeneration.
Using LV-derived GFP as a reliable and specific intracellular marker for implanted OEG, no migration of these cells over larger distances both proximal and distal from the lesion into the spinal cord was observed. Others, using Hoechst dye as a label to track implanted cells, have reported migration of OEG over large distances and hypothesised that this resulted in the long-distance regeneration of lesioned spinal axons through and beyond OEG implants. 20, 21, 36 However, identification of implanted cells based on Hoechst-labelling has to be interpreted very carefully because of the potential leakage of Hoechst dye from implanted cells into the neighbouring host tissue. 56, 57 Our present study, using viral vector-mediated gene transfer, suggests an alternative view which is that this regeneration is in fact not a result of OEG migrating along with regenerating axons. In all rats, GFP-labelled OEG could be detected in the central compartment of the scar tissue, intermingling with GFAP-positive reactive astrocytes surrounding the lesion site, but OEG did not migrate across the astrocytic barrier into the host spinal cord. These results suggest that injected OEG into lesion sites are supportive 'bridging' substrates for CNS axons to cross the hostile scar environGene Therapy ment, but that migration of OEG is not necessary for long-distance regeneration. There is evidence showing that intact adult myelinated white matter tracts can be highly permissive for regeneration, 58 supporting the suggestion that OEG migration is not a prerequisite for regeneration beyond the lesion site.
In summary, these results demonstrate that both AdV and LV vectors are useful tools for ex vivo gene transfer to OEG and can be exploited in future studies to enhance regeneration in the injured CNS. Furthermore, stable transduction of OEG using LV vectors can be used to reliably track implanted cells, and obtain better understanding of OEG behaviour and signalling in the lesioned spinal cord. As discussed earlier, the use of OEG implants as cellular conduits to stimulate regeneration in the injured CNS may have some advantages over the use of Schwann cells or fibroblasts making them ideal cellular targets for genetic engineering and neurotrophic factor production. Moreover, the recent identification and characterisation of a human olfactory ensheathing cell, with properties very similar to rat OEG, 59 opens possibilities for future clinical applications.
Materials and methods
Experimental animals
Adult female Fischer (F344) inbred rats (175-200 g; Harlan, Oxford, UK) were housed under standard conditions. All animals had free access to water and food. The animal experiments were conducted in accordance with the guidelines of the local animal care committee.
Viral vector production
The AAV-2 vector used in this study was constructed by inserting 'humanized' GFP. 60 Briefly, GFP cDNA was cloned into pcDNA I/AMP yielding the plasmid pc5- GFP. Subsequently, pTR-CMV-GFP was constructed by insertion of the transgene expression cassette between the inverted terminal repeats (ITRs) of pTR-UF. Downstream of the GFP cDNA, the cis-acting woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was cloned in to enhance vector-derived transgene expression. 61, 62 The construction of the helper plasmid pDG, needed for the production of recombinant AAV-2 vector particles, was described previously. 63 Recombinant AAV-2 particles were produced as described by the method of Hermens and colleagues. 64 Briefly, the vector plasmid pTR-CMV-GFP and the helper plasmid pDG were co-transfected into HEK 293T cells using calcium phosphate precipitation. The medium was replaced after 6 h and the cells were incubated for 48 h at 37°C and 5% CO 2 . Next, the cells were dislodged, harvested and freeze-thawed three times to release AAV particles from the cells. Cell debris was removed using low-speed centrifugation. The supernatant was loaded on a Matrix Cellufine-sulphate bead column (Amicon, Danvers, MA, USA). After several washings with 0.1 m phosphate-buffered saline pH 7.4 (0.9% NaCl; PBS), the virus was eluted from the column with PBS containing 1 m NaCl. Next, viral particles were banded on an Iodixanol (Nycomed Pharm, Oslo, Norway) density gradient using ultracentrifugation and fractions of about 300 l were collected from the bottom of the gradient. Recombinant AAV-2 stock titres were determined by an infectious unit centre assay, 65 and were in the range of 10 10 infectious units/ml. To reduce viscosity of the Iodixanol, AAV-2-containing fractions were diluted 10 times with PBS and re-concentrated on a Centricon-100 concentrator (Amicon).
Figure 4 Analysis of AdV vector-mediated gene expression in OEG following implantation into the lesioned spinal cord. Schematic representations of a C4 RST lesion (top right) and plane of sectioning (top left) are shown. Horizontal sections through the lesion area show numerous implanted OEG expressing high levels of the transgene at 7 days after implantation, as determined by immunohistochemical staining for ␤-gal. A gradual decline in the number of transgene-expressing cells can be observed in time, and transgenic ␤-gal expression is almost completely lost at 30 days after implantation. However, the detection of many
First generation replication-deficient AdV vector stocks encoding the bacterial marker gene ␤-gal were produced using standard procedures as described previously. 66, 67 Briefly, an AdV-targeting plasmid was generated by insertion of an expression unit of the LacZ gene, under the control of the CMV promoter, downstream of the adenovirus serotype 5 (AdV-5) ITR (map units 0-1.25) and upstream of the map units 9.2-15.5 of the wild-type AdV genome. The AdV-targeting plasmid was linearised by SalI digestion. The AdV-5 dl309 DNA was digested with ClaI and XbaI, deleting the E1 gene region of the viral genome. Linearised targeting plasmid was then cotransfected with digested wild-type AdV DNA into the human retinoblastoma 911 producer cells. 68 Plaques were isolated and characterised by PCR for the right recombinant viral clone. Next, purified plaques were expanded on 911 cells, isolated and purified by two rounds of CsCl density gradient centrifugation. Recombinant AdV bands were collected from the gradient, dialysed against TS buffer pH 7.4 (137 mm NaCl, 6 mm KCl, 0.7 mm Na 2 HPO 4 , 1.1 mm MgCl 2 , 0.9 mm CaCl 2 , 25 mm Tris-HCl) and stored in TS buffer containing 10% glycerol at -80°C. Titres of AdV vector stocks were determined using Gene Therapy plaque assays on 911 cells and expressed as plaque forming units per ml (p.f.u./ml). Stock titres were in the range of 10 10 -10 11 p.f.u./ml. The production of self-inactivating LV vectors has been described in detail previously. 69 The plasmids needed for the production of GFP-encoding LV vector were generously provided by Drs L Tamagnone and L Naldini (Institute for Cancer Research, University of Torino, Italy). Stocks of LV-GFP were generated by cotransfection of three plasmids, the viral core packaging construct pCMVdeltaR8.74, the VSV-G envelope protein vector pMD.G.2, and the transfer GFP vector pRRLsinPPThCMV-GFP-wpre into HEK 293T cells. 70, 71 In brief, a total of 5 × 10 6 cells were seeded in 10-cm dishes 24 h before transfection in Iscove's modified Dulbecco culture medium, containing 10% foetal calf serum, penicillin (100 IU/ml), 100 g/ml streptomycin and 2 mm Glutamax (Sigma, Zwijndrecht, The Netherlands). The culture medium was refreshed 2 h before transfection. Using a modified calcium phosphate method, HEK 293T cells were transfected with 3.5 g envelope plasmid, 6.5 g packaging plasmid and 10 g GFP-expressing gene transfer plasmid per 10-cm dish. The next day, the medium was refreshed. Virion-containing medium was harvested 24 h later, and debris removed from the medium by lowspeed centrifugation and filtering through a 0.22-m cellulose acetate filter. The number of transducing particles was defined by infecting HEK 293T cells and counting the number of GFP-expressing cells after 48 h. Recombinant stock titres were expressed as transducing units (TU) per ml and ranged in the order of 10 7 TU/ml. 
OEG cultures and purification
Primary OEG cultures were prepared as described previously. 21 Adult (3-4 months old) female Fischer rats were killed by an overdose of Nembutal (Rhone Merieux, Pinkenba, Queensland, Australia), and the olfactory bulbs dissected and put into Leibovitz's-15 medium (L-15) (Sigma, St Louis, MO, USA). The pia was carefully removed and the olfactory nerve fibre and glomerular layers were dissected away from the rest of the bulb. The tissues were then cut into 1-mm 3 pieces and incubated with 0.25% trypsin (GibcoBRL, Grand Island, NY, USA) containing 50 mg/ml DNase (GibcoBRL) at 37°C for 60 min with continual shaking. Trypsinisation was stopped by adding Dulbecco's modified Eagle's medium (DMEM; Sigma) and Ham's F-12 (D/F-12; Sigma; 1:1 mixture) supplemented with 10% foetal bovine serum (DF-10S; GibcoBRL) and 50 mg/ml gentamicin (GibcoBRL).
The method for the purification of OEG from primary cultures was modified from the original protocol. 21 After 6-7 days, the OEG were separated from the other cells in the primary cultures by immunoaffinity, using an antibody against p75 NTR . The cells in primary culture were detached using 0.05% trypsin and 0.02% EDTA (GibcoBRL), centrifuged and washed twice with DF-10S. These cells were suspended in L-15 medium and plated on 100-mm petri dishes that had been pretreated with a series of antibodies as follows. Firstly, 100-mm dishes were incubated overnight at 4°C with a mixture of antimouse IgG, IgA and IgM antibodies (1:100; ICN Biomedicals, Seven Hills, New South Wales, Australia) and were washed three times with L-15 medium. The dishes were
Gene Therapy then incubated with p75 NTR antibody (a gift of Dr P Wood, University of Miami School of Medicine, Miami, FL, USA) at 1:5 dilutions in L-15 medium with 5% foetal bovine serum for 2 h at 4°C. The dishes were then washed three times with L-15 medium, and a 10-ml suspension of cells from the olfactory bulbs was plated on to the antibody-treated dishes at a density of 4 × 10 5 cells per dish for 30 min at 4°C. The dishes were washed five times with L-15 medium to remove unbound cells from the dishes. The bound cells were then removed from the dishes with a cell scraper (Sarstedt, Newton, NC, USA), centrifuged and re-suspended in DF-10S. The cells were then seeded on to poly-l-lysine-coated 100-mm dishes and fed with DF-10S containing 20 g/ml pituitary extract and 2 m forskolin (Sigma).
Ex vivo transduction of OEG cultures
To determine transduction efficiency of cultured OEG using AAV-2, AdV and LV vectors, cells were seeded on to poly-l-lysine-coated 24-well plates at a density of 10 5 cells per well and fed overnight with DF-10S containing 20 g/ml pituitary extract and 2 m forskolin. The next day, the medium was replaced with DF-10S containing 2 g/ml pituitary extract and 0.2 m forskolin to reduce OEG proliferation. Recombinant AAV-2, AdV and LV vectors encoding the bacterial marker gene ␤-gal (AdVLacZ) or GFP (AAV-GFP, LV-GFP) respectively, were added with increasing MOI (AAV-2: MOI 1, 50, 100, 500, 1000; AdV: MOI 1, 5, 10, 25, 50, 100 and 250; LV: MOI 1, 5, 10, 25, 50) to each well. Cultures were analysed for transgene expression 3 or 7 (in case of AAV-2 infection) days after infection by enzymatic staining of ␤-gal using the 5-bromo-4-chloro-3-indolyl ␤-d-galactosidase substrate (X-gal staining) or immunocytochemistry for GFP (1:50; rabbit polyclonal antibody; Chemicon, Harrow, UK) using standard procedures with 3,3'-diaminobenzidine tetrachloride (DAB) as a chromophore.
Preparation of transduced OEG suspensions for implantation
Primary cultured OEG were detached by trypsinisation, centrifuged and washed twice in DF-10S. These cells were resuspended in DF-10S, counted and seeded into 60-mm dishes at a density of 10 6 cells per dish. Cells were fed overnight with DF-10S containing 2 g/ml pituitary extract and 0.2 m forskolin. The medium was then replaced by medium containing 10 8 p.f.u. AdV-LacZ (MOI 100) or 10 7 TU LV-GFP (MOI 50). The next day, cells were pre-labelled using 10 g/ml Hoechst 33342 (bis-benzimide; Sigma) for 3 min at 37°C. Cultures were then washed three times with L-15 medium, detached by trypsinisation, centrifuged and washed twice with serum-free D/F-12. Cells were resuspended in D/F-12, counted and pelleted by low-speed centrifugation. Pelleted OEG were carefully resuspended in an appropriate volume of D/F-12 yielding an OEG suspension of 10 5 cells/l. Viability of OEG suspensions were in the range of 95-100% as determined by trypan blue staining. Suspensions were kept on ice until the end of surgical procedures.
Surgery
Adult female Fischer F344 rats (n = 32; 175-200 g) were deeply anaesthetised intramuscularly with ketamine (100 mg/kg body weight; Nimatek, Eurovet, Bladel, The Netherlands) and xylazine (10 mg/kg body weight; Rompun, Bayer, Leverkussen, Germany). The neck musculature was split at the midline and the cervical spinal cord exposed by dorsal laminectomy of the fourth cervical vertebra (C4). Next, the dura was opened using a small hooked 30-G needle allowing direct access to the spinal cord. For implantation of transduced OEG in lesioned spinal cord, the dorsolateral funiculus of the spinal cord containing the RST was lesioned with a pair of microscissors. First, the midline of the spinal cord and dorsal root entry zone were identified. Next, the left dorsolateral funiculus was cut, as deep as 1 mm from the dorsal surface of the spinal cord (Figure 4) . Such a lesion completely disrupted the dorsolateral funiculus, including the RST, and partially lesioned the grey matter. The rostrocaudal extent of the lesion cavity was approximately 0.5-1 mm. Suspended OEG were microinjected 1 mm proximal and distal from the lesion site (1 l; approximately 10 5 cells) per injection (depth 0.6 mm) using a small glass capillary (tip diameter 60 m) attached to 10 l Hamilton syringe needle. In case of OEG implantation in the intact spinal cord, a similar surgical procedure was followed, except for unilateral lesioning of the dorsolateral spinal cord. OEG suspensions were directly injected into the dorsolateral funiculus (1 l approximately 10 5 cells), in the vicinity of the RST. Injections were performed using a Harvard microinjection apparatus (0.2 l per min for 5 min). The injector was left in place for 1 min to allow diffusion from the injection site and then carefully removed. Muscles and skin were closed in separate layers. Animals received a post-operative subcutaneous injection of 2 ml physiological salt solution, to compensate for blood loss, and Finadyne (2.4 mg/kg body weight; Schering-Plough, Brussels, Belgium) to suppress pain. At the end of surgery, viability of OEG suspensions was still over 95% as determined by trypan blue staining.
Tissue preparation
Animals were killed at the survival times of 1, 2, 4 and 16 weeks (LV-transduced OEG only) weeks after implantation (n = 4 per time-point). The rats were deeply anaesthetised with sodium pentobarbital (75 mg/kg body weight i.p.; Nembutal, Sanofi Sante, Maassluis, The Netherlands) and transcardially perfused with 100 ml saline followed by 300 ml ice-cold 4% paraformaldehyde (PFA) in PBS. Spinal cords were carefully dissected and post-fixed overnight in 4% PFA solution at 4°C. The tissue was then washed several times with PBS, embedded in 10% gelatine (Difco, Detroit, MI, USA) in PBS, and fixed overnight in 4% PFA solution at 4°C. 72 Consecutive horizontal vibratome sections (40 m) were cut in PBS and collected in serial vials.
Immunohistochemistry
Vibratome sections were washed three times in Tris-buffered saline pH 7.4 (10 mm Tris/HCl). To enhance tissue penetration and block unspecific antibody binding sites, sections were incubated in PBS containing 0.3% Triton X-100 and 5% foetal calf serum for 1 h at room temperature. Adjacent sections were double immunolabelled for the transgene product ␤-gal (gal-13, 1:2000; mouse monoclonal antibody, Sigma) or GFP (1:50; rabbit polyclonal antibody, Chemicon), p75 NTR (1:50; mouse monoclonal antibody, Roche Diagnostics, Almere, The Netherlands) and GFAP (1:1000; rabbit polyclonal antibody; Dako, Carpinteria, CA, USA). To visualise NF-positive axons, implanted OEG and reactive astrocytes at the lesion site, native GFP fluorescence was used, combined with immunolabelling for NF (1:1000; mouse monoclonal antibody 2H3; Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) and GFAP. For all stainings, primary antibody incubations were performed overnight at 4°C. The next day, sections were washed and incubated with a mixture of fluorophore-conjugated secondary antibodies for 1 h at room temperature: SAR-FITC/DAR-Cy5 (depending on whether native GFP fluorescence was used which interfered with FITC signal) and DAM-Cy3 (all 1:400; Jackson ImmunoResearch Lab-oratories, West Grove, PA, USA). Sections were mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA) and coverslipped. Digital photo-images were captured using a Zeiss confocal laser scanning microscope and imported Adobe Photoshop 5.5.
